CREPT (Cell-cycle-related and expression-elevated protein in tumor)/RPRD1B, a novel protein that enhances the transcription of Cyclin D1 to promote cell proliferation during tumorigenesis, was demonstrated highly expressed in most of tumors. However, it remains unclear how CREPT is regulated in colorectal cancers. In this study, we report that miR-383 negatively regulates CREPT expression. We observed that CREPT was up-regulated but the expression of miR-383 was down regulated in both colon cancer cell lines and colon tumor tissues. Intriguingly, we found that enforced expression of miR-383 inhibited the expression of CREPT at both the mRNA and protein level. Using a luciferase reporter, we showed that miR-383 targeted the 3′-UTR of CREPT mRNA directly. Consistently we observed that over 
while p15RS inhibits the cell proliferation by inhibiting Wnt signaling. 3, 4 Our previous observations showed that CREPT bound to both the promoter region and the region before the Poly-A signal in the termination region of the CCND1 gene. 1 We discovered that CREPT mediated chromatin loop formation for the CCND1 gene, which may facilitate the recycling of RNAP II during the transcription of genes in mammalian cells. 1, 5 Recently, our lab revealed that CREPT participated in the transcription of Wnt/β-catenin signal target genes through the β-catenin and TCF4
complex. 6 We found that CREPT interacted with both β-catenin and TCF4, and enhanced the association of β-catenin with TCF4, resulting in activation of Wnt signaling, which further promotes tumor cell growth. 6 Consistent with our findings, Jung et al 7 reported that CREPT, together with seven other genes, was significantly elevated in SV40-immortalized cells and NSCLC tissues. Additionally, Wang et al 8 reported that CREPT was significantly up-regulated in endometrial cancer tissues and promoted tumor growth by accelerating cell cycle. Using the monoclonal antibody against CREPT, 9 She et al 10 reported that high expression of CREPT is correlated with poor prognosis in retroperitoneal leiomyosarcoma, similar to our previous observations that CREPT is related to prognosis in gastric cancers. 1 CREPT is also reported to be involved in the DNA damage repairing, indicating a role in regulation of genome stability. 11, 12 Together, accumulating evidence suggests that CREPT plays an important role in tumorigenesis by elevated expression. However, the molecular mechanisms responsible for the regulation of CREPT expression remain unclear.
MicroRNAs (miRNAs) are short endogenous non-coding RNAs that are involved in many cellular functions including regulation of cell proliferation, apoptosis, differentiation, and metabolism. 13, 14 miRNAs regulate gene expression by binding to complementary sequences, preferentially within the 3′-untranslated region (3′-UTR) of target messenger RNA (mRNA), to inhibit translation by promoting RNA degradation or destabilization. [15] [16] [17] Usually, miRNAs target mRNAs with an average 3′ length of 1600 nucleotides but rarely target mRNA with a 3′ containing less than 1000 nucleotides. 18 Our preliminary analysis indicated that CREPT mRNA contains a long 3′ (2486 nucleotides), implying a post-transcriptional regulation by miRNAs. In this study, we found that miR-383 directly targets the 3′-UTR of CREPT mRNA. We observed an inverse correlation between the expressions of miR-383 and CREPT in colorectal tumor cell lines and human colorectal tumor tissues. Our study illuminates a novel mechanism of CREPT expression regulation in colorectal cancers.
| MATERIALS AND METHODS

| Cell culture
CCD-841 CoN (normal colon epithelial), 293T, and human colon cancer cell lines SW-480, HCT-116, DLD-1, HT-29 were purchased from American Type Culture Collection (ATCC, Manassas, VA) and passaged according to the ATCC protocol. HCT116 β/W cell line is a derivate from wild type HCT-116 cell by introduction of a heterozygous mutant β-catenin in HCT-116. 19 
| Reporter plasmids and the luciferase reporter assay
To construct a luciferase reporter plasmid, the wildtype 3′-UTR of CREPT, including the predictive miR-383 binding site, was amplified using primers (Supplementary Table S2 ) and cloned into a psiCHECK2.0 Dual-Luciferase Reporter system (C8021, Promega, CREPT, respectively. Cells were collected every day for 4 days and counted using a hemocytometer after trypan blue staining as previously reported. 23 Cell viability was determined using a 3-(4,5-dimethyltiazole-2-yl)-2.5-diphenyltetrazolium bromide (MTT) assay as described previously. 24 In brief, cells were transfected with miR-383 mimic, NC mimic, CREPT siRNA, miR-383 together with pcDNA3.1-CREPT and NC together with pcDNA3.1, respectively, in a 6-well plate 24 h later, cells were re-seeded into a 96-well plate in triplicate. After 4-6 days (or until ∼90% confluency of NC treatment group), cell medium was replaced with WST-8 (SigmaAldrich, Carlsbad, CA) dye for 1-5 h. The absorbance was quantified using a microplate reader at 450 nm.
| Colony formation assay
Colony formation assays were performed using KM12SM cells were housed under identical conditions were allowed free access to a standard diet and tap water and exposed to a 12 h light: 12 h dark cycle. The nude mice were injected s.c. with 5 × 10 6 KM12SM cells stably transfected pcDNA 3.1, pcDNA3.1-pre-miR-383, or pcDNAmiR-383-sponge, respectively, on the back of mice. Tumor growth was measured using calipers every two days. The tumor volume was calculated as Tumor Volume = (length × width 2 )/2 as was used previously. 24 
| Statistics
All results in this study were statistically presented as mean ± standard errors. Two-way ANOVA and chi-square test was used to analyze the significance of the cell growth curve and xenografts tumor growth studies. P < 0.05 was considered to be statistically significant by Student's t-test. *P < 0.05, **P < 0.01, and ***P < 0.001.
3 | RESULTS
| CREPT is abundantly expressed in colon cancer cell lines and clinical samples
Our previous studies demonstrated that CREPT is highly expressed in many cancers as compared to that in adjacent non-tumor tissues. 1 In this study, we show that the mRNA level of CREPT is abundantly expressed in a panel of colorectal cancer cells while hardly detected in a normal colon epithelial cell line, CCD841
( Figure 1A ). Similarly, the protein level of CREPT in the colorectal cancer cells remains at high level while no protein is shown in the normal cell ( Figure 1B ). In order to understand the clinical relevance in colorectal cancer, we analyzed the expression of CREPT mRNA in the tumor and adjacent normal tissues from 18 pairs of patient samples. The results showed that CREPT mRNA was elevated in 13 patient samples (72%) of colorectal tumors as compared to adjacent non-tumor tissues ( Figure 1C ). This is consistent with our previous observation that CREPT protein expression was highly expressed in 75% of patient colon cancer tissue samples. 1 All the results suggest that CREPT is abundantly expressed in colorectal cancers.
| Identification of CREPT-targeting miRNAs
To elucidate the molecular mechanism for the overexpression of CREPT in colorectal cancers, we determined to analyze how the CREPT mRNA is up-regulated. As high level of mRNA may be a product from accelerated transcription and increased stability of mRNA, we were in particular interested in whether CREPT mRNA is stabilized in tumors in this study. Interestingly, our preliminary analysis demonstrated that CREPT has a long 3′-untranslated region (UTR) of 2486 colorectal cancer patients comparing with that in the adjacent nontumor tissues ( Figure 2F ). Interestingly, we also observed that miR-383 level was increased in four tumors. Overall, we performed an analysis on the correlation of CREPT and miR-383 expression in tumor patients and obtained a very strong reversed correlation (P < 0.05) ( Figure 2G ).
All these results suggest that the expression of miR-383 is negatively correlated to the expression of CREPT in colorectal cancer cells and tissues, implying a negative regulation mechanism of CREPT expression by miR-383.
| miR-383 regulates the expression of CREPT directly
To validate whether CREPT is a direct target of miR-383, we engineered a luciferase reporter containing the 3′-UTR of the CREPT mRNA. As controls, we generated luciferase reporters with a mutation or deletion within the predicted miR-383 binding site in the CREPT mRNA 3′-UTR ( Figure 3A) . The KM12SM and HCT116
β/W cells were transiently transfected with the CREPT 3′-UTRreporters along with miR-383 or its mimics (negative control) for a luciferase assay. The results showed that transfection of different dosages of miR-383 led to a significant decrease in the reporter activity in comparison with the maximal amount of mimics in both KM12SM and HCT116 β/W cells ( Figure 3B ). At the same time, we observed that transfection of miR383 failed to inhibit the luciferase activity in the mutated reporters where miR383 binding site was mutated or deleted ( Figure 3C ). These results suggest that miR-383 inhibits the luciferase activity via a direct interaction with the CREPT 3′-UTR.
To reveal whether miR383 plays a role on the mRNA stability, we examined the half-life of CREPT mRNA. The results showed that ectopic miR-383 overexpression dramatically deceased the half-life of CREPT mRNA, while an inhibitor against miR-383 slightly prolonged the half-life ( Figure 3D ).
To further verify the effect of miR383 on the endogenous CREPT expression, we transfected miR-383 with or without a CMV-driven cDNA CREPT expression vector where no 3′-UTR exists. A Western blot analysis demonstrated that miR-383 inhibits the endogenous expression of CREPT, but fails to inhibit the exogenous CREPT expression ( Figures 3E and 3F ). Taken together, our results suggest that miR-383 negatively regulates CREPT expression directly by binding to its mRNA 3′-UTR.
| Overexpression of miR-383 inhibits the CREPTmediated transcriptional activity and Wnt signaling
As miR-383 targets CREPT for its expression, we reasoned that miR-383 might be able to regulate the expression of genes downstream of CREPT. As our previous study revealed that These results suggest that miR-383 modulates the expression of CyclinD1, CDK6, and CDK4 through inhibition of CREPT expression.
As our previous study showed that CREPT enhances the activity of the β-catenin/TCF4 complex to initiate transcription of Wnt target genes, 6 we next determined to examine whether miR-383 regulates the Wnt signaling pathway. For this purpose, we transfected miR-383 with a Wnt-responsive luciferase reporter, superTOP-luciferase, into both KM12SM and HCT116 β/W cell lines, where endogenous CREPT expressed was high (see Figure 1) .
A luciferase report experiment result demonstrated that transfection of miR-383 significantly decreased the luciferase activity either at the basal level or under the stimulation of Wnt conditional medium in both KM12SM and HCT116 β/W cells ( Figure 4E ). As a control, an inhibitor of miR-383 failed to decrease the luciferase activity ( Figure 4E , last columns in each group). These results showed the over-expression of miR-383 failed to inhibit the luciferase activity ( Figure 4F ). This result indicate that miR-383
inhibits Wnt/β-catenin signaling pathway, by negatively regulating the expression of CREPT. . E, Luciferase assays demonstrated that miR-383 significantly reduced Wnt signaling in both KM12SM and HCT116 β/W cells where endogenous CREPT with miR-383 targeted sequence at its 3′UTR is highly expressed (see Figure 1) . A specific luciferase reporter in response to Wnt signal was used. Note that miR-383 inhibitor (383 Inh) failed to inhibit the reporter activity. F, Over-expression of miR-383 failed to inhibit the luciferase activity mediated by a vector-based CREPT, which had no miR-383 targeted sequence at the 3′-UTR.
All the results were presented as means of three independent experiments ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 5C). In a colony formation assay, we observed that KM12SM cells transfected with miR-383 formed as much less colonies as those transfected with an siRNA against CREPT ( Figures 5D and 5E ). These results suggest that miR383 inhibits cell proliferation and colony formation; similar to that from depletion of CREPT, implying that the inhibition effect of miR-383 might be through, at least in part, by negatively regulating CREPT expression.
We further examined the effect of miR-383 on the cell cycle in colon cancer cells. A flow cytometry analysis showed that the percentage of G1 phase cells dramatically increased in the miR-383 
| DISCUSSION
In our previous study, we found that CREPT is preferentially highly expressed in diverse human tumors and the overexpression of CREPT accelerates tumor growth. 1 Other reports have focused on the function of CREPT, its downstream target genes and the mechanism responsible for CREPT mediated tumor progression. 1, 7, 8, 10 However, how CREPT expression during the tumorigenesis is regulated remained elusive. In this study, we found that CREPT mRNA has a long 3′, accounting for about 64% of the whole length of mRNA. We speculated that this long 3′ sequence provides a chance for the regulation of the expression after transcription. Indeed, we revealed that miR-383 binds to the 3′ sequence to down regulate mRNA stability and its translation, through its partial complementary binding, as occurs in most cases. 27, 28 We have Another issue in this study is that miR-383 may function on the regulation of tumorigenesis independent of CREPT. In our study, we found that miR383 is one of the miRNAs targeting CREPT mRNA.
Although we did not examine the role of other miRNAs on the regulation of CREPT expression, this study provided clear evidence that miR-383 is a major one to down regulate the expression of CREPT at the post-transcriptional level. Indeed, our data showed that over- CCND1 in glioma cells. 37 Our data showed that miR-383 regulates the expression of CCND1 in response to Wnt signaling. We speculate that miR-383 on the glioma may also through CREPT expression, which eventually regulated the expression of CCND1 as reported previously. 1, 6 In this study, our results indicate that miR-383 inhibits FIGURE 7 Working model. CREPT is highly expressed in tumors and functions to promote tumorigenesis. miR-383 targets the 3′UTR of CREPT mRNA to un-stabilize it thereafter to inhibit the activity of CREPT. As CREPT interacts with both β-catenin and TCF4 to enhance the association of β-catenin with TCF4, in response to Wnt signaling for the expression of targeted mRNA, cylinD1, CDK4, and CDK6, miR383 also inhibit these gene expression. We proposed that miR-383 could act as a tumor suppressive microRNA, in part by negatively regulating CREPT expression and subsequently Wnt/β-catenin signaling pathway Wnt/β-catenin signaling pathway, by negatively regulating the expression of CREPT and further inhibit the proliferation, colony formation, and tumorigenesis. We speculated that miR-383 could exert its anti-proliferative effects by multiple signaling pathways through targeting multiple proteins in colorectal cancer. Further studies are needed to confirm this speculation.
In conclusion, we revealed that miR-383 mediates binds to the 3′UTR of CREPT mRNA, leading to the unstable maintenance and impaired translation. In such a way, miR383 functions as a negative regulator to guard the cell with a low level of CREPT protein.
Eventually, high level of miR-383 overcomes the oncogenic protein CREPT and prevent the cells from becoming tumor cells. As most of the tumor is induced by over-activation of Wnt signaling, we propose that the miR-383, by inhibition of CREPT expression, can block the Wnt signaling, at least in part, to decrease the expression of tumor related genes including CyclinD1, CDK4, and CDK6 ( Figure 7) . Our study provided a clue for diagnosis/prognosis of colorectal cancers using decreased level of miR-383.
